Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

  • Technology appraisal guidance
  • TA798
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Expected publication